STANDARD BIOTOOLS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.42 USD | -5.65% |
|
-7.28% | +9.50% |
Financials (USD)
| Sales 2024 * | 201M | Sales 2025 * | 232M | Capitalization | 926M |
|---|---|---|---|---|---|
| Net income 2024 * | -161M | Net income 2025 * | -69M | EV / Sales 2024 * | 4.61 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 3.99 x |
| P/E ratio 2024 * |
-5.63
x | P/E ratio 2025 * |
-13.4
x | Employees | 537 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.94% |
More Fundamentals
* Assessed data
More news
Latest transcript on Standard BioTools Inc.
More recommendations
More press releases
More news
| 1 day | -5.65% | ||
| 1 week | -7.28% | ||
| Current month | -10.70% | ||
| 1 month | -9.70% | ||
| 3 months | +3.42% | ||
| 6 months | +10.50% | ||
| Current year | +9.50% |
1 week
2.40
2.65
1 month
2.403.04
Current year
1.743.04
1 year
1.463.16
3 years
0.927.51
5 years
0.9214.30
10 years
0.9246.38
| Managers | Title | Age | Since |
|---|---|---|---|
Michael Egholm
CEO | Chief Executive Officer | 61 | 22-04-03 |
Jeffrey Black
DFI | Director of Finance/CFO | 55 | 23-05-14 |
Shane Bowen
CTO | Chief Tech/Sci/R&D Officer | - | Jan. 04 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 70 | 22-03-31 | |
Fenel Eloi
BRD | Director/Board Member | 66 | 23-03-14 |
Kathy Hibbs
BRD | Director/Board Member | 60 | Jan. 04 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 2.42 | -5.47% | 2,332,094 |
| 24-04-23 | 2.56 | +0.79% | 2,265,813 |
| 24-04-22 | 2.54 | +0.79% | 2,286,002 |
| 24-04-19 | 2.52 | -0.79% | 2,753,470 |
| 24-04-18 | 2.54 | -2.68% | 2,831,907 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotes
Standard BioTools Inc. develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines. The Company's segments include Proteomics and Genomics. The Proteomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of genes and their functions. The Company provides insights in health and disease using its mass cytometry and microfluidics technologies, which serve applications in proteomics and genomic. It works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories around the world, focusing on the needs in translational and clinical research, including oncology, immunology, and immunotherapy. The Company also provides differentiated multi-omics tools for research.
Calendar
2024-05-01
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.42
USD
Average target price
3.583
USD
Spread / Average Target
+48.07%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.50% | 926M | |
| +8.78% | 220B | |
| +8.24% | 185B | |
| +11.16% | 133B | |
| +26.12% | 107B | |
| +0.19% | 62.91B | |
| +16.21% | 53.34B | |
| -1.63% | 47.71B | |
| -1.11% | 40.29B | |
| +12.16% | 39.57B |
- Stock Market
- Equities
- LAB Stock
